Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) EBT: 2021-2023

Historic EBT for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to -$39.7 million.

  • Cullinan Therapeutics' EBT fell 37.10% to -$39.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$169.2 million, marking a year-over-year decrease of 211.83%. This contributed to the annual value of -$167.5 million for FY2024, which is 1.04% up from last year.
  • According to the latest figures from Q4 2023, Cullinan Therapeutics' EBT is -$39.7 million, which was down 1.28% from -$39.2 million recorded in Q3 2023.
  • Cullinan Therapeutics' EBT's 5-year high stood at $240.1 million during Q2 2022, with a 5-year trough of -$58.1 million in Q1 2023.
  • For the 3-year period, Cullinan Therapeutics' EBT averaged around -$7.1 million, with its median value being -$30.6 million (2022).
  • The largest annual percentage gain for Cullinan Therapeutics' EBT in the last 5 years was 1,560.76% (2022), contrasted with its biggest fall of 2,387.53% (2022).
  • Cullinan Therapeutics' EBT (Quarterly) stood at -$34.2 million in 2021, then rose by 15.38% to -$28.9 million in 2022, then slumped by 37.10% to -$39.7 million in 2023.
  • Its last three reported values are -$39.7 million in Q4 2023, -$39.2 million for Q3 2023, and -$32.2 million during Q2 2023.